<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121120">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02041871</url>
  </required_header>
  <id_info>
    <org_study_id>P120207</org_study_id>
    <nct_id>NCT02041871</nct_id>
  </id_info>
  <brief_title>Interest of PReOPerative Immunonutrition in Liver Surgery for Cancer</brief_title>
  <acronym>PROPILS</acronym>
  <official_title>Interest of Preoperative Immunonutrition in Liver Resection for Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nestlé Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the efficacy of preoperative immunonutrition in reducing postoperative morbidity
      after liver resection for cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perioperative immunonutrition has been developed to improve the immuno metabolic host
      response and outcome in postoperative period and has been proven to be beneficial in
      reducing significantly postoperative infectious complications and length of hospital stay in
      patients undergoing elective gastrointestinal surgery for tumors. To date, the effects of
      preoperative oral immunonutrition (ORAL IMPACT) in non cirrhotic patients undergoing liver
      resection for cancer are unknown. The purpose of this study is to determine whether the
      administration of a short-term preoperative oral immunonutrition can reduce postoperative
      morbidity in non-cirrhotic patients undergoing liver resection for malignant tumours.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall complications classified in grade 2-3-4 or 5 by DINDO-CLAVIEN</measure>
    <time_frame>In the first 30 postoperative days after Liver surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>30 days after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hepatectomy</condition>
  <condition>Elective Hepatectomy</condition>
  <condition>Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>Impact control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ORAL IMPACT Powder 74g within 250ml of water, 3 times per day during 7 days before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral immunonutrition</intervention_name>
    <description>Powder 74g within 250ml of water, 3 times per day during 7 days before surgery</description>
    <arm_group_label>Impact control</arm_group_label>
    <other_name>ORAL IMPACT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Powder 74g within 250ml of water, 3 times per day during 7 days before surgery</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PLACEBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Non cirrhotic patient

          -  Elective liver surgery for cancer (primary or secondary malignant tumours)

          -  Hepatectomy including at least 1 segment or 3 wedge resections

        Exclusion Criteria:

          -  Liver resection for benign lesions

          -  Liver resection associated with biliary tract surgery

          -  Liver resection associated with gastro-intestinal surgery

          -  Cirrhosis, defined by transient elastography (Fibroscan®) or by liver biopsy

          -  Renal failure

          -  Pregnancy or nursing women

          -  History of hypersensitivity or allergy to arginine, omega-3 fatty acids, or
             nucleotides

          -  Inability to take oral nutrition

          -  Mental condition rendering the subject unable to understand the nature, end-points
             and consequences of the trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis CASTAING, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oriana CIACIO, MD</last_name>
    <phone>+33 (1) 45 59 64 32</phone>
    <email>oriana.ciacio@pbr.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thibault VORON</last_name>
    <phone>+33 (1) 45 59 64 32</phone>
    <email>thibault.voron@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AP-HP, Paul Brousse Hospital, Centre Hepato-Biliaire</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oriana CIACIO, MD</last_name>
      <email>oriana.ciacio@pbr.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Oriana CIACIO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>January 20, 2014</lastchanged_date>
  <firstreceived_date>January 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Surgery</keyword>
  <keyword>Hepatectomy</keyword>
  <keyword>Immunonutrition</keyword>
  <keyword>Cancer</keyword>
  <keyword>Morbidity</keyword>
  <keyword>Postoperative complication</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
